BiotechTube

PF-08046876

Phase 1Recruiting
1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced/Metastatic Solid Tumors

Conditions

Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer

Trial Timeline

Aug 20, 2025 → Jul 8, 2029

NCT ID
NCT07090499

About PF-08046876

PF-08046876 is a phase 1 stage product being developed by Pfizer for Advanced/Metastatic Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07090499. Target conditions include Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma.

What happened to similar drugs?

0 of 2 similar drugs in Advanced/Metastatic Solid Tumors were approved

Approved (0) Terminated (0) Active (2)
🔄Pembrolizumab + Lenvatinib + Oxaliplatin + Capecitabine + Leucovorin (or Levoleucovorin) + 5-FUEisaiPhase 3
🔄eftilagimod alfa + carboplatin plus paclitaxel + cisplatin or carboplatin + pemetrexed + pembrolizumab (KEYTRUDA®)MerckPhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07090499Phase 1Recruiting

Competing Products

20 competing products in Advanced/Metastatic Solid Tumors

See all competitors
ProductCompanyStageHype Score
Recombinant oncolytic virus M1, anti PD-1 antibody, ApatinibSun PharmaceuticalPhase 1
25
Pembrolizumab + Lenvatinib + Oxaliplatin + Capecitabine + Leucovorin (or Levoleucovorin) + 5-FUEisaiPhase 3
44
PF-05082566 + KW-0761Kyowa KirinPhase 1
21
eftilagimod alfa + carboplatin plus paclitaxel + cisplatin or carboplatin + pemetrexed + pembrolizumab (KEYTRUDA®)MerckPhase 3
44
MK-4464 + Pembrolizumab + 89Zr-MK-4464MerckPhase 1
29
ADG126 + Pembrolizumab (KEYTRUDA®) + Standard of Care (Trifluridine/Tipiracil-Bevacizumab) + Standard of care (Fruquintinib)MerckPhase 1/2
39
Selumetinib + PembrolizumabMerckPhase 1
21
BJ-001 + PembrolizumabMerckPhase 1
25
ADG116MerckPhase 1
29
Gebasaxturev IV + Gebasaxturev ITu + PembrolizumabMerckPhase 2
27
ADU-S100 + ipilimumabNovartisPhase 1
21
simlukafusp alfa + Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody + Gemcitabine + VinorelbineRochePhase 2
27
Selicrelumab + Vanucizumab + BevacizumabRochePhase 1
29
AMG 510AmgenPhase 1
33
PF-08634404 + Sigvotatug Vedotin + Combination Agent 1PfizerPhase 1/2
39
Capecitabine + SunitinibPfizerPhase 2
35
IBI308Innovent BiologicsPhase 1
29
MM-121 + PaclitaxelSanofiPhase 1
29
Ubamatamab + REGN7075 + SarilumabRegeneron PharmaceuticalsPhase 2
42
ALLO-647 + Fludarabine + CyclophosphamideAllogene TherapeuticsPhase 1
27